JAZZ logo

JAZZ Jazz Pharmaceuticals plc

NASDAQ · Biotechnology · Healthcare

$236.38
-11.39 (-4.60%)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC);…

Market Cap: $15.17Bwww.jazzpharma.com

Price

No data yet.

Social Signal Score

39
5d
10
1 mentions
—
30d
47
11 mentions
—
60d
48
15 mentions
—
90d
52
33 mentions
—
news: 33

Analyst Ratings

48 analysts
Buyconsensus
Strong Buy 0Buy 43Hold 5Sell 0Strong Sell 0
Avg price target$295.73+25.1%
Low $220Median $300High $337
Current Consensus

Revenue

$1.24B+213.40%
$376.05M$665.04M$954.02M$1.24B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$8.23
$7.80–$9.18
11 analysts
FY2026
$14.93+81% YoY
$13.85–$15.83
12 analysts
FY2027
$26.84+80% YoY
$22.95–$31.99
12 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Renee D. Gala
Sector
Healthcare
Industry
Biotechnology
Employees
2,890
Beta
0.32
Country
IE
Piotroski score
7 / 9 (Strong)
Altman Z-score
2.00
www.jazzpharma.com